`
`Page 1 of 1
`
`®
`™
`ACHN (ATCC CRL-1611 )
`
`Organism: Homo sapiens, human / Tissue: kidney; derived from metastatic site: pleural effusion / Disease: renal cell adenocarcinoma
`
`GENERAL INFORMATION
`
`CHARACTERISTICS
`
`CULTURE METHOD
`
`SPECIFICATIONS
`
`HISTORY
`
`DOCUMENTATION
`
`SHARE
`
`
`
`Derivation
`
`The ACHN cell line was initiated in November, 1979 from the
`
`malignant pleural effusion of a 22-year-old Caucasian male with
`
`widely metastatic renal adenocarcinoma (autopsy confirmed).
`
`Cells were seeded directly to culture flasks in Eagle's MEM with
`
`10% FBS, then maintained and passaged 150 days in flasks.
`
`Cells were then inoculated subcutaneously into nude mice. After
`
`4 weeks, palpable, locally invasive tumors were noted. Both the
`
`original cells (ACHN) and those recovered from nude mouse
`
`tumors were growth-inhibited by human interferons.
`
`Clinical Data
`
`22 years
`Caucasian
`male
`
`Tumorigenic
`
`Yes
`
`Effects
`
`Yes, in nude mice
`(Tumors developed within 21 days at 100% frequency (5/5) in
`nude mice inoculated subcutaneously with 10(7) cells)
`
`Comments
`
`Growth is inhibited by human interferon [Hogan, T. F., personal
`communication].
`
`https://www.atcc.org/Products/All/CRL-1611.aspx?&p=1&rel=characteristics
`
`3/29/2018
`
`NOVARTIS EXHIBIT 2086
`Breckenridge v. Novartis, IPR 2017-01592
`Page 1 of 1
`
`